Risk factors for early treatment discontinuation in patients with obsessive-compulsive disorder

被引:10
|
作者
Diniz, Juliana Belo [1 ]
Malavazzi, Dante Marino [1 ]
Fossaluza, Victor [1 ,2 ]
Belotto-Silva, Cristina [1 ]
Borcato, Sonia [1 ]
Pimentel, Izabel [1 ]
Miguel, Euripedes Constantino [1 ]
Shavitt, Roseli Gedanke [1 ]
机构
[1] Univ Sao Paulo, Sch Med Hosp Clin, Dept & Inst Psychiat, Sao Paulo, Brazil
[2] Univ Sao Paulo, Math & Stat Inst, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
Obsessive-compulsive disorder; Anxiety disorders; Somatoform disorders; First-line treatments; Patient compliance; BECK DEPRESSION INVENTORY; PORTUGUESE VERSION; BEHAVIOR-THERAPY; SCALE; PREDICTORS; TRIAL; COMBINATION; VALIDATION; EXPOSURE;
D O I
10.1590/S1807-59322011000300004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION: In obsessive-compulsive disorder, early treatment discontinuation can hamper the effectiveness of first-line treatments. OBJECTIVE: This study aimed to investigate the clinical correlates of early treatment discontinuation among obsessive-compulsive disorder patients. METHODS: A group of patients who stopped taking selective serotonin reuptake inhibitors (SSRIs) or stopped participating in cognitive behavioral therapy before completion of the first twelve weeks (total n = 41; n = 16 for cognitive behavioral therapy and n = 25 for SSRIs) were compared with a paired sample of compliant patients (n = 41). Demographic and clinical characteristics were obtained at baseline using structured clinical interviews. Chi-square and Mann-Whitney tests were used when indicated. Variables presenting a p value < 0.15 for the difference between groups were selected for inclusion in a logistic regression analysis that used an interaction model with treatment dropout as the response variable. RESULTS: Agoraphobia was only present in one (2.4%) patient who completed the twelve-week therapy, whereas it was present in six (15.0%) patients who dropped out (p = 0.044). Social phobia was present in eight (19.5%) patients who completed the twelve-week therapy and eighteen (45%) patients who dropped out (p = 0.014). Generalized anxiety disorder was present in eight (19.5%) patients who completed the twelve-week therapy and twenty (50%) dropouts (p = 0.004), and somatization disorder was not present in any of the patients who completed the twelve-week therapy; however, it was present in six (15%) dropouts (p = 0.010). According to the logistic regression model, treatment modality (p = 0.05), agoraphobia, the Brown Assessment of Beliefs Scale scores (p = 0.03) and the Beck Anxiety Inventory (p = 0.02) scores were significantly associated with the probability of treatment discontinuation irrespective of interactions with other variables. DISCUSSION AND CONCLUSION: Early treatment discontinuation is a common phenomenon in obsessive-compulsive disorder patients from our therapeutic setting. Psychiatric comorbidities were associated with discontinuation rates of specific treatments. Future studies might use this information to improve management for increased compliance and treatment effectiveness.
引用
收藏
页码:387 / 393
页数:7
相关论文
共 50 条
  • [1] Risk factors for delaying treatment seeking in obsessive-compulsive disorder
    Demet, Mehmet Murat
    Deveci, Artuner
    Taskin, E. Oryal
    Dundar, Pinar Erbay
    Ermertcan, Aylin Turel
    Demet, Selin Mizrak
    Bayraktar, Dilek
    Ozturkcan, Serap
    [J]. COMPREHENSIVE PSYCHIATRY, 2010, 51 (05) : 480 - 485
  • [2] CLOMIPRAMINE IN THE TREATMENT OF PATIENTS WITH OBSESSIVE-COMPULSIVE DISORDER
    DEVEAUGHGEISS, J
    [J]. ARCHIVES OF GENERAL PSYCHIATRY, 1991, 48 (08) : 730 - 738
  • [3] Risk factors prospectively associated with adult obsessive-compulsive symptom dimensions and obsessive-compulsive disorder
    Grisham, J. R.
    Fullana, M. A.
    Mataix-Cols, D.
    Moffitt, T. E.
    Caspi, A.
    Poulton, R.
    [J]. PSYCHOLOGICAL MEDICINE, 2011, 41 (12) : 2495 - 2506
  • [4] GENETIC AND ENVIRONMENTAL FACTORS AND RISK OF OBSESSIVE-COMPULSIVE DISORDER
    Mahjani, Behrang
    Klei, Lambertus
    Hultman, Christina
    Larsson, Henrik
    Devlin, Bernie
    Buxbaum, Joseph
    Sandin, Sven
    Grice, Dorothy
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S249 - S249
  • [5] Treatment of obsessive-compulsive disorder
    Dar, R
    [J]. CURRENT OPINION IN PSYCHIATRY, 1996, 9 (02) : 125 - 128
  • [6] The treatment of obsessive-compulsive disorder
    de Haan, E
    [J]. CLINICAL PSYCHOLOGY & PSYCHOTHERAPY, 2001, 8 (05) : 380 - 387
  • [7] TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
    MARKS, I
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1995, 167 : 411 - 412
  • [8] Treatment of obsessive-compulsive disorder
    Stein, Dan J.
    Ipser, Jonathan C.
    Baldwin, David S.
    Bandelow, Borwin
    [J]. CNS SPECTRUMS, 2007, 12 (02) : 28 - 35
  • [9] RETURN OF SYMPTOMS AFTER DISCONTINUATION OF CLOMIPRAMINE IN PATIENTS WITH OBSESSIVE-COMPULSIVE DISORDER
    PATO, MT
    ZOHARKADOUCH, R
    ZOHAR, J
    MURPHY, DL
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 1988, 145 (12): : 1521 - 1525
  • [10] Early Recognition of Obsessive-Compulsive Disorder
    Juckel, Georg
    Siebers, Frauke
    Kienast, Thorsten
    Mavrogiorgou, Paraskevi
    [J]. JOURNAL OF NERVOUS AND MENTAL DISEASE, 2014, 202 (12) : 889 - 891